Review anchor
Adenosine receptor
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Adenosine receptor
CHEMBL2111329
PROTEIN FAMILY
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Adenosine receptor as ChEMBL target CHEMBL2111329, mapped to UniProt P30542. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2111329
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P30542
Adenosine receptor A1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Adenosine receptor matters
Adenosine receptor is reviewed as Adenosine receptor A1 (UniProt P30542); Adenosine receptor shows approved-linked disease relevance led by Airway obstruction. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 24 compounds, and 9 assays, with lead potency reaching pChEMBL 5.3.
Protein context
Adenosine receptor A1
Adenosine receptor A1 Sequence length is 326 aa.
Review this target as Adenosine receptor, mapped to UniProt P30542. ChEMBL maps the protein component as Adenosine receptor A1. Sequence length is 326 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P30542
Protein
Disease context
Airway obstruction
Adenosine receptor shows approved-linked disease relevance led by Airway obstruction. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AMINOPHYLLINE, OXTRIPHYLLINE, THEOPHYLLINE.
Start review with Airway obstruction because it currently carries approved-linked support. Linked drugs include AMINOPHYLLINE, OXTRIPHYLLINE, THEOPHYLLINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
3 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 24 compounds, and 9 assays for this target. The dominant activity type is EC50. CHEMBL4168653 is the current potency anchor at pChEMBL 5.3.
Use CHEMBL4168653 as the tractability anchor when discussing potency (pChEMBL 5.3).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 5.3
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Adenosine receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P30542, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why Airway obstruction is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
24
Total Compounds
9
Total Assays
0
Approved Drugs
IC50: 1.0, KI: 1.0, EC50: 4.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4168653
|
5.3 | EC50 | — |
|
|
No preferred name
CHEMBL4163380
|
5.1 | EC50 | — |
|
|
No preferred name
CHEMBL2112109
|
4.4 | Ki | — |
|
|
No preferred name
CHEMBL4167064
|
4.2 | EC50 | — |
|
|
No preferred name
CHEMBL273807
|
4.2 | EC50 | — |
Source Header